PhRMA’s Compromise Offer On Drug Safety Would “Clarify” FDA’s Powers
Executive Summary
The Pharmaceutical Research and Manufacturers of America is proposing reforms to FDA's safety powers that would allow quicker regulatory actions, but not fundamentally alter the agency's authority
You may also be interested in...
FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden
Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies
FDA Bill Passes; Congress Adds $225 Million To Industry User Fee Burden
Final FDA reform legislation that cleared Congress adds an additional $225 million to industry's user fee tab over five years, but limits penalties that FDA can assess to enforce its new authorities to mandate labeling changes and postmarket studies
Preemption Remains Conference Issue In FDA Bill As Both Sides Declare Victory
The impact of FDA reform legislation on product liability lawsuits could depend in large part on how the House and Senate resolve subtle differences in phrasing between the two chambers' bills